‌

This activity was funded by Alnylam Pharmaceuticals. The medical content was developed independently by M3 and Professor Violaine Planté-Bordeneuve.

Highlights from

Amyloidosis Conferences

VIRTUAL, APRIL - OCTOBER 2021

AAN, EAN, ESC-HF, PNS, ESC, EU-ATTR and WCN
SCROLL TO ARTICLES

    Articles

    Diagnosis

    Cardiac imaging in ATTR amyloidosis

    Identifying ATTR-CM: are we doing enough?

    Clinical trials

    Tafamidis treatment in ATTRv-PN: clinical and real-world evidence

    HELIOS-A: positive 9-month results with an investigational RNAi for patients with hATTR amyloidosis and polyneuropathy

    Patisiran in hATTR amyloidosis: beyond the APOLLO phase III study

    Long-term efficacy and safety of an antisense oligonucleotide inhibitor in hATTR amyloidosis with polyneuropathy

    Tafamidis treatment in patients with ATTR-CM

    Emerging therapies

    The future landscape of ATTR-CM treatment

    A single-dose alternative to gene silencing therapies in hATTR? Results from the first in-human demonstration of CRISPR-based gene editing therapy

    What is the potential of antisense drugs for rare neurological disease?

    Key factors for the diagnosis and management of ATTR amyloidosis

    Neurofilament light chain (NfL): a potential biomarker of disease progression and treatment response?

    Patient outcomes

    What can we learn from patient-reported outcomes in hATTR amyloidosis?

    Outcomes with patisiran in patients with hATTR amyloidosis with polyneuropathy post-orthotopic liver transplantation

    Why early intervention matters in cardiac hATTR amyloidosis

    Amyloidosis 2021 review

    Amyloidosis 2021 review

    Top image: Eraxion

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    Supported by